Cancer Discovery

Article	Citations
AI-Supported Mammography “Safe,” Cuts Workload	6470
HLA-E:CD94–NKG2A Mediates Circulating Tumor Cell Immune Evasion	681
Mutation-Driven Alveolar Cell Reprogramming Dictates Lung Cancer Progression	349
Succinyl-CoA and Cobalamin Are Biomarkers That Improve Anal Cancer Screening	312
Human Tumor Cells Display an Oncogene-like Addiction to Aneuploidy	253
Q&A: Philip Greenberg on T Cells, IO's Future	246
Shattered Chromosomes Undergo Mitotic Tethering during Chromothripsis	229
PARADIGM Identifies Associations between Drugs, the Microbiome, and Mortality	222
Air Pollution Promotes Oncogenic Expansion of Mutant Lung Progenitor Cells	210
Transposable Element Signatures Define Stages of T-cell Exhaustion	206
Probing Clonal Hematopoiesis in Liquid Biopsy	205
Collagen Receptor Implicated in Immune Exclusion	204
Low-Glycemic Diets Restrict Tumor Growth through Altered Lipid Metabolism	200
Drafting a Blueprint for European Cancer Research	194
IL7 Genetic Variation Predicts Immune-Related Adverse Events	194
Dendritic Cell Circadian Rhythm Governs the Antitumor Immune Response	190
Mouse Models Provide Insight into Factors Affecting BiTE Efficacy	180
Highlighted research articles	171
Proteostasis Network Modulation Promotes Resistance to KRAS Inhibitors	167
REFLECTions on Combination Therapies Empowered by Data Sharing	166
Highlighted research articles	160
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission	150
Correction: Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer	146
Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers	146
PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway	145

A Guide to Extrachromosomal DNA: Cancer’s Dynamic Circular Genome	143
Selpercatinib Shifts Treatment Paradigm for MTC and NSCLC	143
GIST: Molecular Profiling Suggests 2nd Therapy	142
Exome Sequencing IDs Hidden Disease Variants	137
Cytosolic Phospholipase A2 Determines Intercellular Heterogeneity of Stress Granules and Chemotherapy Response	136
Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors	134
Combination Diagnostics: Adding Blood-Based ctDNA Screening to Low-Dose CT Imaging for Early Detection of Lung Cancer	128
Trispecifics Improve Immune-Cell Engagement	128
Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma	128
Visualizing Cancer Heterogeneity at the Molecular and Cellular Levels: Lessons from Rosetta	127
An NK-cell Therapy for CD30+ Lymphomas	126
Lymph Node Metastasis Induces Immune Tolerance and Distant Metastasis	125
RAS Drives Malignancy through Altered Stem Cell/Microenvironment Cross-talk	125
Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?	124
The 3D Revolution in Cancer Discovery	123
Neuro-Mesenchymal Interaction Mediated by a β2-Adrenergic Nerve Growth Factor Feedforward Loop Promotes Colorectal Cancer Progression	121
Intrinsic Properties of the Lymph Node Render It Immunologically Susceptible to Metastasis	121
Gut Microbiota Modulation through Akkermansia spp. Supplementation Increases CAR T-cell Potency	118
Structure of the Tumor Stroma Predicts Invasive Breast Cancer Relapse	117
Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma	116
p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression	113
CHD2 Regulates Neuron–Glioma Interactions in Pediatric Glioma	112
A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy	111
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors	109
Multicellular Spatial Organization Determines Immunotherapy Response	107
Presurgery Plus Postsurgery Immunotherapy Ups Survival in NSCLC	107
Response to Low Antigen Density Is Improved by HLA-Independent T-cell Receptors	105
In This Issue	105
Chronic Inflammation Drives TP53-Mutant Leukemic Evolution	105
Tumor-Derived Extracellular Vesicles and Particles Inhibit Liver Function	104
The Proteasome Regulator PSME4 Modulates Antitumor Immunity	104
Intestinal Microbiome Inhibits CD8+ T Cells via the Calcineurin–NFAT Axis	103
New Strategy May Thwart Glioblastoma Resistance	101
FMRP Depletion Reprograms an Immunosuppressive Microenvironment	101
TILs Outperform Ipilimumab in Melanoma	99
Hyperactivation of Oncogenic Pathways Hinders Cancer Cell Survival	99
Lymph Node–Specific IFNγ Levels Affect CD8+ T-cell Priming against Tumors	96
Revumenib Is Safe and Efficacious, but MEN1 Mutations Mediate Resistance	93
What's Next for Sotorasib in NSCLC?	93
Biomarker Testing Falls Short in NSCLC	90
Aged Lungs Enable Metastatic Outgrowth of Dormant Melanoma Cells	90
In This Issue	89
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients	88
Cancer in the Prime of Life: Etiologic Insights and Supportive Oncologic Interventions for the Rising Burden of Young Adult Cancer	88
Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy	87
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer	86
Oncogenic KRAS-Dependent Stromal Interleukin-33 Directs the Pancreatic Microenvironment to Promote Tumor Growth	86
A Molecular Voyage: Multiomics Insights into Circulating Tumor Cells	85
Akk Abundance Alters Survival in Patients with NSCLC on ICIs	85
Noninvasive and Multicancer Biomarkers: The Promise of LINE-1 Retrotransposons	84

Bridging the Gap between Diseases of the Stomach and Lower Esophagus	84
Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology	83
Harnessing Mitochondrial Mutations to ATAC Clonal Evolution in CLL	83
Atypical Small Cell Lung Cancer: A New Malignancy Characterized by Chromothripsis, Carcinoid Tumors, and Wild-type RB1 and TP53	80
New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma	80
Rlf–Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer	80
NRF2: KEAPing Tumors Protected	79
Beneath the Surface: Neoantigens beyond Chromosomal DNA Mutations	79
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity	79
Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer	79
A Transitional Cell Population Is Enriched in Aggressive Human Medulloblastoma	78
Study Sniffs Out New Glioma Mechanism	78
ABBV-383 Demonstrates Tolerability and Efficacy in Relapsed/Refractory MM	78
Chromatin Remodeling Factors Drive Epigenetic Changes Crucial for T-cell Exhaustion	77
Distinct Clonal Patterns Exist between Benign and Malignant Tissue	76
A Spatiotemporal Positive Feedback Loop Exists Between TAMs and CD8+ T Cells	76
IL6 Blockade Reduces Immunotherapy-Induced Immune-Related Adverse Events	75
Lasker Honors Discovery of Cell Adhesion Molecules	74
Resistant KRAS(G12C) Inhibitor Subclones Exhibit Heterogeneous Alterations	73
Ibrutinib with R-CHOP Differentially Affects Genetic Subtypes of DLBCL	72
Blinatumomab Nonresponse Is Associated with Poor CD19-CAR Outcome in B-ALL	71
The Kinase Module of the Mediator Complex Inhibits CAR T-cell Function	70
MEDI5752 Suppresses Two Immune Checkpoints	69
MCED Testing Enters New Diagnostic Realms	69
Prenatal Chemotherapy and Its Impact on the Genome of Fetal Hematopoiesis	69
Q&A: Robert Vonderheide on Immunotherapy Advances	68
Heritable Defects in Mitotic and Telomere Function Confer Sarcoma Risk	67
Air Pollution–Lung Cancer Link Identified	67
Cancer Cells Adapt to SWI/SNF Inhibition through Compensatory EP400 Function	67
Cancer Neuroscience of Brain Tumors: From Multicellular Networks to Neuroscience-Instructed Cancer Therapies	66
Advancing Global Health Equity in Oncology Clinical Trial Access	66
Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML	66
Sex Hormone Signaling Suppresses Ferroptosis via Phospholipid Remodeling	66
Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation	65
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts	65
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes	65
MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation	65
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma	65
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors	64
Human Colon Cancer–Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice	64
Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia	64
Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer	64
CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool	63
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities	63
The Hallmarks of Predictive Oncology	63
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer	62
Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs	62
Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2	62
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	62
Distinct Treatment-Related Immunologic Biomarkers Are Identified in PDAC	61
Carcinogenic Human Metabolites Are Revealed Using “Metabokiller”	61
Glioma Infiltration and Progression Are Driven by Remote Neuronal Activation	60
Surface Expression of NRP1 on Tregs Affects Outcome in Patients with Cancer	59
Structure of the Ligand-Bound HER2–HER3 Dimer Reveals a Dynamic Interface	59
ESCRT Protein Inhibition Enhances CTL-Mediated Cytolysis of Tumor Cells	58
Court Rulings Complicate Decisions for Pregnant Patients	58
Silent Mutations Reveal a Novel Treatment for RASQ61 Cancers	58
A Deep Learning Model for Cancer Type Prediction Sets a New Standard	58
VCAM1 Mediates Innate Immune Tolerance of Hematopoietic and Leukemic Stem Cells	57
Gut Microbiota May Mediate AEs	57
The Evolutionary History of Breast Cancer and Related Clones Is Revealed	56
IL4 Signaling in the Bone Marrow Promotes Protumorigenic Myelopoiesis	56
Antitrust Order Aimed at Equalizing MCED Field	56
The APOE–TREM2 Axis Mediates Senescent Neutrophils in Prostate Cancer	55
Heterologous Cancer Vaccines plus Checkpoint Inhibitors Show Therapeutic Benefit	55
Glucose Metabolism in TAMs Promotes Metastasis and Drug Resistance	55
Epitope Editing Prevents Off-Tumor Toxicity of CAR T-cell Therapy in AML	53
Gene-Specific Machine Learning Models to Classify Driver Mutations in Clonal Hematopoiesis	53
Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer	53
Peto’s Paradox Is Dead. Long Live Peto’s Paradox	53
Illuminating a Dark Kinase in the Mesenchymal Cancer Cell State	53
HeLa Cases Prompt More Thinking on Ethics	53
Highlighted Research Articles	53
If You Build It, Patients with Rare Cancers Will Come: A Successful Clinical Trial in Relapsed and Refractory JMML	53
Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer	52
Bacterial Genotoxin Accelerates Transient Infection–Driven Murine Colon Tumorigenesis	52
Methylation Is Best for cfDNA Multicancer Early Detection Tests	52
Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation	52
Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas	52
When Cancer Cells Become the Enablers of an Antitumor Immune Response	51

CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary	51
The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade	51
Stromal KITL/SCF Maintains Pancreas Tissue Homeostasis and Restrains Tumor Progression	51
Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors	50
Tissue-Agnostic Drug Development: A New Path to Drug Approval	50
Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors	50
SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors	50
Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia	50
Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence	49
DietaryLactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy	49
Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity	49
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer	48
Cancer-Associated Fibroblasts Serve as Decoys to Suppress NK Cell Anticancer Cytotoxicity in Breast Cancer	48
A Whole Cancer Cell–Based Vaccine Boosts Cell Killing and Antitumor Immunity	48
Specific Anatomic Transcriptomes Drive Oncogenesis in Melanoma	47
A Bacterial-Based Immunotherapy for PDAC	47
Tumor-Reactive Antibodies Emerge from Nonbinding and Autoreactive Precursors	47
Molecular Profiles Distinguish Brain Metastases of Diverse Neural Impact	47
Distinct Mutational Processes Influence Germline DNA Mutations	46
ImmunoGen Takeover Caps Year of Record ADC Investments	46
Structure of SHOC2–PP1C–RAS Reveals a Mechanism of RAF Activation	46
Antitumor Plasma Cells Mature Within Tertiary Lymphoid Structures	46
Homing In on RNA Fusions in Breast Cancer	46
Atypical EGFR Mutations Show Heterogeneity	45
Culture Media Tweak Makes Heartier CARs	45
Acknowledgment to Reviewers	44
Acknowledgment to Reviewers	44
A Base Editing Platform Shows Function of Cancer-Associated Variants	44
Kidney Cancer Researcher Tapped as NCI Director	44
Tumor Microenvironment Immune Changes Support Anti-CD19 CAR T-cell Efficacy	43
HER2 Expression Impacts Trastuzumab Deruxtecan Efficacy in Breast Cancer	43
In This Issue	43
An Atlas of Tumor Metabolism Uncovers Gene–Metabolite Interactions	42
TNF Receptors Choose HSC Fate in SupportingDnmt3a-Mutant Clonal Hematopoiesis	42
Lymphocyte Interaction Networks Drive Lung Cancer Immunosurveillance	42
Precision Cancer Medicine: Large Studies Indicate Steady Progress	42
Pushing the Boundaries of Liquid Biopsies for Early Precision Intervention	41
Loss of p53 Induces Tolerance to Viral Mimicry as a Mechanism of Immune Evasion in Early Tumorigenesis	41
Correction: High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability	41
Clonal GCB Cells Support Angioimmunoblastic T-cell Lymphoma Tumorigenesis	40
Cancer-Causative Mutations Occurring in Early Embryogenesis	38
So Grateful for My X: Sex Chromosomes Drive Differences in Glioblastoma Immunity	38
Condensate-Promoting ENL Mutation Drives Tumorigenesis In Vivo Through Dynamic Regulation of Histone Modifications and Gene Expression	38
ATM Inhibition Sensitizes ALT Neuroblastomas to Chemotherapy	38
Insights and Opportunity Costs in Applying Spatial Biology to Study the Tumor Microenvironment	38
IFNα Potentiates Immune-Checkpoint Blockade by Rewiring Metabolic Cross-talk	37
Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma	37
Radical Collaboration: Reimagining Cancer Team Science	37
Highlighted Research Articles	37
DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming	37
Artificial Intelligence and Machine Learning Technologies in Cancer Care: Addressing Disparities, Bias, and Data Diversity	35
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy	35
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting	35
The Bispecific Antibody Epcoritamab Produces Responses in Lymphoma	34
Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer	34
Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial Calcium	34
Biomolecular Condensation: A New Phase in Cancer Research	33
Machine Learning Models ID Cancer Drivers	33
Dual Immunotherapy Makes Strides against HCC	33
Single-Cell Tumor–Normal Analysis Proposes Combinatorial CAR Strategies	33
Y Chromosome Loss Drives Bladder Cancer Aggressiveness and Immune Evasion	33
In This Issue	33
In This Issue	33
Altered tRNA Isoacceptor Abundance Regulates Breast Cancer Metastasis	33
Ibrutinib Treatment in Early Stage CLL Prolongs Time to Active Disease	32
HSCT Chemotherapy Supports Peripheral Macrophage Engraftment of the Brain	32
Approved Drugs May Reduce Anthracycline Drug–Related Cardiotoxicity	32
Colonic Microbiota Promote Antitumor Immunity in Colorectal Cancer	32
Noted	32
Moonshot Redux to Focus on Prevention, Screening	32
On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors	32
Q&A: Ted Laetsch on Tumor-Agnostic Therapies	31
Senescent Cancer Cells Are Vulnerable to Extrinsic Apoptosis Pathway Activation	31
A High-Fat Diet Controls MHC Class II on ISCs via the Microbiome	31
MHC-I Cross-Dressing Supports Antitumor CD8+ T-cell Priming	31
BTK Inhibitor Options Expand for CLL/SLL	31
Driver Events of Gastric Cancer Differ According to Subtype and Ancestry	30
Correction: Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development	30
Nociceptor Neurons Affect Immunosurveillance and Tumor Growth	30
High-Endothelial Venules Promote Permissive T-cell Niches after Immunotherapy	30
Disruption of KAT8–IRF1 Condensate Formation Reduces PD-L1 Expression	30
Correction: Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy	30
Primary, Metastatic Tumors Vary Genomically by Cancer Type	29
Germline-somatic liaison dictates cancer subtype via de novo steroid biosynthesis	29
Gut Microbiota Regulate PD-L2 Expression and Immunotherapy Response	29
PHGDH Inhibition Overcomes Glioblastoma Resistance to T-cell Therapy	29
Artificial Intelligence Identifies Novel Disease Pathways	29
Intrinsically Disordered Regions Control cBAF Condensation and Interactions	29
HPV42, a “Low-Risk” Type, and Digital Papillary Adenocarcinoma	29
Correction: Animal Alternatives OK'd by New Law	27
Mitochondrial glutathione import enables breast cancer metastasis via integrated stress response signaling	27
Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer	27
Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines	27
Dangerous Liaisons betweenTet2Mutation, Inflammatory Monocytes, and Leukemogenesis	27
Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts	26